Boulogne-Billancourt, Ile-de-France, France Ipsen is the famous Corporate Investor, which was founded in 1929. The main office of represented Corporate Investor is situated in the Boulogne-billancourt. The venture was found in Europe in France.
Speaking about the real fund results, this Corporate Investor is 9 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2017. The important activity for fund was in 2019. This Ipsen works on 4 percentage points more the average amount of lead investments comparing to the other organizations.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Ipsen, startups are often financed by New Enterprise Associates, MPM Capital, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are Third Rock Ventures, New Enterprise Associates, MPM Capital. In the next rounds fund is usually obtained by Third Rock Ventures, SV Health Investors, Pfizer Venture Investments.
The current fund was established by Henri Beaufour.
Among the most popular fund investment industries, there are Biotechnology, Health Care. Among the various public portfolio startups of the fund, we may underline Thesan Pharmaceuticals, Pyxis Oncology, Pyxis Oncology For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Related Funds
| Fund Name | Location |
| Alkermes | County Dublin, Dublin, Ireland |
| Apex Capital | New York, New York, United States |
| Bisheng Keji | China, Hangzhou, Zhejiang |
| Capital One | Illinois, United States, Virginia |
| Dexia | Arcisses, Centre-Loire Valley, France |
| Finpiemonte | - |
| Kerogen Digital Solutions | - |
| Korea Asset Investment Securities | - |
| Lympo | California, San Diego, United States |
| Marubun Corporation | Japan, Tokyo |
| Prudence Investment Management | China, Hong Kong, Hong Kong Island |
| Qianhai Pengchen Investment | China, Guangdong, Shenzhen |
| Ralph T. and Esther L. Warburton Foundation | - |
| Roynat Equity Partners | Alberta, Calgary, Canada |
| SIGMA Ventures | Brentwood, Tennessee, United States |
| Sprout Group | New York, New York, United States |
| Viadeo | France, Ile-de-France, Paris |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
BAKX Therapeutics | $25M | 18 Nov 2021 | Kingston, New York, United States | ||
Pyxis Oncology | $152M | 30 Mar 2021 | Boston, Massachusetts, United States | ||
Xilio Therapeutics | $100M | 02 Mar 2020 | Massachusetts, United States | ||
Pyxis Oncology | $22M | 17 Jul 2019 | Boston, Massachusetts, United States | ||
Purer Skin | $40M | 13 Aug 2015 | Boston, Massachusetts, United States | ||
Thesan Pharmaceuticals | $49M | 24 Feb 2014 | Carlsbad, California, United States | ||
Motus Therapeutics | $8M | 27 Nov 2012 | Boston, Massachusetts, United States | ||
Motus Therapeutics | $25M | 13 Jun 2012 | Boston, Massachusetts, United States | ||
Syntaxin | $29M | 11 Nov 2010 | Vale of White Horse, England, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
BAKX Therapeutics | $25M | 18 Nov 2021 | Kingston, New York, United States | ||
Pyxis Oncology | $152M | 30 Mar 2021 | Boston, Massachusetts, United States | ||
Xilio Therapeutics | $100M | 02 Mar 2020 | Massachusetts, United States | ||
Pyxis Oncology | $22M | 17 Jul 2019 | Boston, Massachusetts, United States | ||
Purer Skin | $40M | 13 Aug 2015 | Boston, Massachusetts, United States | ||
Thesan Pharmaceuticals | $49M | 24 Feb 2014 | Carlsbad, California, United States | ||
Motus Therapeutics | $8M | 27 Nov 2012 | Boston, Massachusetts, United States | ||
Motus Therapeutics | $25M | 13 Jun 2012 | Boston, Massachusetts, United States | ||
Syntaxin | $29M | 11 Nov 2010 | Vale of White Horse, England, United Kingdom |
